A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
Latest Information Update: 18 Apr 2022
Price :
$35 *
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms ProPSMA
- 18 Jun 2019 As per source record Anticipated date last participant enrolled: 1/20/2020 and Actual date last participant enrolled: 11/2/2018
- 18 Jun 2019 Planned initiation date changed from 16 Jan 2017 to 14 Mar 2017.
- 18 Jun 2019 Status changed from recruiting to active, no longer recruiting.